Amgen Inc. has patented indazole-containing compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Researchers from Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have discovered GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Genentech Inc. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Windermere Therapeutics Inc. has disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Gilead Sciences Inc. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.

GTPase KRAS G12D mutant and/or G12V mutant inhibitors potentially useful for the treatment of cancer have been detailed in a Quanta Therapeutics Inc.

Sanofi SA has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Bayer AG has synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Tyligand Bioscience Ltd. has identified new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.